Clinical Trials Directory

Trials / Conditions / Raynaud's Disease

Raynaud's Disease

16 registered clinical trials studyying Raynaud's Disease — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingOpen Label Treprostinil Raynaud's Study
NCT07112183
Brigham and Women's HospitalPhase 4
CompletedDiosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
NCT02683408
Primus PharmaceuticalsN/A
CompletedScleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
NCT02396238
Cytori TherapeuticsN/A
CompletedNova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.
NCT02615964
University of Illinois at Chicago—
CompletedA Two-Part Study of BOTOX® Therapy for Ischemic Digits
NCT01309802
Southern Illinois UniversityPhase 2
CompletedPF-00489791 For The Treatment Of Raynaud's
NCT01090492
PfizerPhase 2
UnknownA Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
NCT00577304
MediQuest TherapeuticsPhase 3
CompletedSafety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
NCT00528242
Response PharmaceuticalsPhase 2
CompletedDose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
NCT00480753
MediQuest TherapeuticsPhase 2
CompletedSt. John's Wort in the Treatment of Raynaud's Phenomenon
NCT00351117
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPhase 3
CompletedPhase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
NCT00419419
MediQuest TherapeuticsPhase 3
CompletedDose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
NCT00378521
MediQuest TherapeuticsPhase 2
CompletedPhase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
NCT00266669
MediQuest TherapeuticsPhase 3
CompletedSafety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenom
NCT00048763
Otsuka America PharmaceuticalPhase 4
CompletedSafety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Pheno
NCT00048776
Otsuka America PharmaceuticalPhase 4
CompletedRaynaud's Treatment Study (RTS)
NCT00000530
National Heart, Lung, and Blood Institute (NHLBI)Phase 3